Protein Kinase Inhibitors: all 15,278 studies that test it

Page 99 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Anlotinib for Patients With Platinum Resistant or Refractory Ovarian CancerStatus unknownNCT03924882Phase 2
• Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast CancerStatus unknownNCT03923179Phase 2
• Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast CancerStatus unknownNCT03923166Phase 2
• A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic DermatitisCompletedNCT03920852Phase 1
• Phase II of Lenvatinib Plus Toripalimab for Advanced HCCWithdrawnNCT03919383Phase 2
• Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated CaSuspendedNCT03919292Phase 1/2
• Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory StudyStatus unknownNCT03919253Phase 2
• Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaActive, not recruitingNCT03919071Phase 2
• Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064CompletedNCT03918980Phase 1
• The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCCStatus unknownNCT03917966Phase 2
• PF-06651600 Taste Study.CompletedNCT03916393Phase 1
• Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy ParticipantsCompletedNCT03916250Phase 1
• A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk TumorsCompletedNCT03914794Phase 2
• A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian SubjectsCompletedNCT03914755Phase 1
• Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer PatientsStatus unknownNCT03913234Phase 1/2
• Apatinib in the Treatment of Recurrence or Metastasis of Esophageal CancerStatus unknownNCT03913182Phase 2
• Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersActive, not recruitingNCT03911973Phase 1/2
• CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET DeregulationStatus unknownNCT03911193Phase 2
• Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBCStatus unknownNCT03910712Phase 2
• Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma AnnulareCompletedNCT03910543Phase 1
• Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)Status unknownNCT03909724Phase 2/3
• Frontline Asciminib Combination in Chronic Phase CMLActive, not recruitingNCT03906292Phase 2
• Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line TherapyCompletedNCT03906058Phase 2
• A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell CarcinomaTerminatedNCT03905889Phase 1
• Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBCTerminatedNCT03905343Phase 3
• Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid TumorsCompletedNCT03905148Phase 1
• A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLCStatus unknownNCT03904823Phase 2
• CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)Status unknownNCT03904719Phase 2
• Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma PatientsStatus unknownNCT03904628Phase 1
• : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid TumorsCompletedNCT03903705Phase 1/2
• Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of InfluenzaActive, not recruitingNCT03901001Phase 3
• Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaCompletedNCT03900949Phase 1
• Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast CancerActive, not recruitingNCT03900884Phase 1
• A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's SyndromeActive, not recruitingNCT03899337Phase 2
• A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung CancerCompletedNCT03898791Phase 1
• Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia AreataActive, not recruitingNCT03898479Phase 2/3
• Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary TumorsCompletedNCT03895970Phase 2
• A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian CancerStatus unknownNCT03895788Phase 1
• PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISISCompletedNCT03895671Phase 2
• A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's LymphomasTerminatedNCT03893682Phase 1
• Fimepinostat in Treating Brain Tumors in Children and Young AdultsActive, not recruitingNCT03893487Early Phase 1
• Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular LymphomaCompletedNCT03892044Phase 1
• Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine TumorsActive, not recruitingNCT03891784Phase 2
• Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung CancerTerminatedNCT03891615Phase 1
• An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver DamageCompletedNCT03890809Phase 1
• A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.CompletedNCT03890770Phase 1
• Anlotinib Maintenance Treatment for Advanced Soft Tissue SarcomaCompletedNCT03890068Phase 2
• Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib HydrochlorideStatus unknownNCT03890055Phase 4
• The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric CancerStatus unknownNCT03889626Phase 3
• Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene AmplificationCompletedNCT03888092Phase 1/2
• Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.TerminatedNCT03886649Phase 1
• Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaActive, not recruitingNCT03884998Phase 1
• A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDSTerminatedNCT03884829Phase 1
• A Safety and Efficacy Study to Evaluate RosaceaWithdrawnNCT03883945Phase 1/2
• A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I MutationStatus unknownNCT03883100Phase 2
• A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I MutationStatus unknownNCT03883087Phase 2
• Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid LeukemiaCompletedNCT03882281Phase 1
• Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue SarcomaStatus unknownNCT03880695Phase 2
• Food Effect Study of CTP-543 in Healthy VolunteersCompletedNCT03880136Phase 1
• Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant MelanomaTerminatedNCT03878719Phase 1
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent PatientsCompletedNCT03877809Phase 2
• A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCCTerminatedNCT03876925Phase 1/2
• A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform LesionsCompletedNCT03876106Phase 1
• Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma PatientsTerminatedNCT03876028Phase 1
• Phase I Trial of Defactinib and VS-6766.Active, not recruitingNCT03875820Phase 1
• A Study of Full Treatment-free Remission in Patients With Chronic Myeloid LeukemiaTerminatedNCT03874858Phase 2
• Study of Crizotinib in Children and Adolescents With Myofibroblastic TumorsStatus unknownNCT03874273Phase 2/3
• A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma PatientsStatus unknownNCT03873532Phase 2/3
• Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy MalesCompletedNCT03873415Phase 1
• norUrsodeoxycholic Acid vs Placebo in PSCActive, not recruitingNCT03872921Phase 3
• Umbilical Cord Blood Transfusion in Progeria SyndromeCompletedNCT03871972Phase 1/2
• A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaActive, not recruitingNCT03871257Phase 3
• Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer PatientsActive, not recruitingNCT03870919Not applicable
• First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid TumorsStatus unknownNCT03869632Phase 1
• Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in ChildrenStatus unknownNCT03868852Phase 1/2
• Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid CancersWithdrawnNCT03868423Phase 2
• Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy VolunteersCompletedNCT03868072Phase 1
• Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNHStatus unknownNCT03866681Phase 4
• A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer PatientsStatus unknownNCT03866499Phase 3
• MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtibActive, not recruitingNCT03865511Phase 2
• A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast CancerStatus unknownNCT03863223Phase 3
• Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib TreatmentStatus unknownNCT03862768Not applicable
• D-0316 in Patients With EGFR Positive Non Small Cell Lung CancerCompletedNCT03861156Phase 2
• Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy AdultsCompletedNCT03858075Phase 1
• Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR MutationStatus unknownNCT03856697Phase 3
• WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 InhibitorCompletedNCT03854903Phase 1
• Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsActive, not recruitingNCT03851614Phase 2
• Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)CompletedNCT03850964Phase 2/3
• A Phase I Study of TQB3616 on Tolerance and PharmacokineticsCompletedNCT03850873Phase 1
• CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).Status unknownNCT03848611Phase 2
• Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast CancerStatus unknownNCT03847818Not applicable
• Tucatinib + Abemaciclib + Herceptin for HER2+ MBCWithdrawnNCT03846583Phase 1
• A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsActive, not recruitingNCT03845166Phase 1
• Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.Status unknownNCT03843749Not applicable
• Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular CarcinomaCompletedNCT03841201Phase 2
• Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung CancerStatus unknownNCT03841136Phase 2
• Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The "UP" StudyCompletedNCT03840005Phase 2
• Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical ResectionStatus unknownNCT03839550Phase 2
• Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/ParagangliomaActive, not recruitingNCT03839498Phase 2

← Protein Kinase Inhibitors overview